Watch EMMA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
53
WATCH · insiders 56, shorts 50
Insiders, 90 days
+$15K
net buying · 4 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.2MP/E —DIV YIELD —FCF YIELD —REV TTM $15.5M +11.0%NET INCOME −$6MNET DEBT $22.2M52W 0.01 – 0.08SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $6.3M | +124.3% | 94.6% | $3.8M | $1.3M | — | 0.02 | $1.7M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $2M | −17.6% | 91.5% | −$823K | −$3.3M | — | -0.05 | −$344K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | $3.9M | +17.0% | 93.9% | $886K | −$2M | — | -0.03 | $2.2M | $0 | $2.2M | Mar 31 |
| Q3 2025 · Sep 30 | $3.4M | −38.3% | 92.7% | $695K | −$2.1M | −213.6% | -0.03 | $409K | $0 | $409K | Nov 14 |
| Q2 2025 · Jun 30 | $2.8M | −47.6% | 94.7% | −$370K | −$1.1M | — | -0.02 | −$2.9M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $2.4M | −4.0% | 90.6% | −$980K | −$2.3M | — | -0.04 | $279K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | $3.3M | −53.4% | 90.6% | −$557K | −$1.7M | −244.6% | -0.03 | $343K | $6K | $337K | Mar 31 |
| Q3 2024 · Sep 30 | $5.5M | +9.2% | 92.8% | $821K | $1.8M | +2626.9% | 0.03 | $148K | −$1K | $149K | Nov 14 |
| Q2 2024 · Jun 30 | $5.4M | — | 95.5% | $582K | −$2.2M | — | -0.03 | −$2.9M | $3K | −$2.9M | Nov 14 |
| Q1 2024 · Mar 31 | $2.5M | — | 89.7% | −$2.7M | −$4.3M | — | -0.07 | $140K | $4K | $136K | Nov 14 |
| Q4 2023 · Dec 31derived | $7.1M | — | 97.3% | $1.4M | $1.2M | — | 0.02 | $1M | $6K | $1M | Apr 14 |
| Q3 2023 · Sep 30 | $5M | — | 95.7% | $24K | $67K | — | -0.01 | $58K | $0 | $58K | Nov 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $12.5M | 93.1% | $231K | −$7.5M | -60.2% | -0.12 | −$11K | $1K | −$12K | — | — |
| FY2024 · to Dec 31 | $16.7M | 92.8% | −$1.9M | −$6.5M | -38.7% | -0.10 | −$2.3M | $12K | −$2.3M | — | — |
| FY2023 · to Dec 31 | $29.6M | 95.5% | $3.5M | −$3.7M | -12.6% | -0.07 | −$1.5M | $17K | −$1.5M | — | — |
| FY2022 · to Dec 31 | $18.4M | 85.9% | −$6.6M | −$10.6M | -57.8% | -0.21 | −$5.1M | $26K | −$5.1M | — | — |
| FY2021 · to Dec 31 | $20.6M | 83.9% | −$6.1M | −$15.9M | -77.4% | -0.32 | −$1.3M | $73K | −$1.3M | — | — |
| FY2020 · to Dec 31 | $23.2M | 90.3% | −$32K | $1.4M | 5.8% | 30.00 | −$2.5M | $15K | −$2.5M | — | — |
Every number comes from Emmaus Life Sciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.